{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:44:07Z","timestamp":1791650647514,"version":"4.3.4"},"reference-count":12,"publisher":"Japanese Urological Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2024,4,20]]},"DOI":"10.5980\/jpnjurol.115.80","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T22:07:17Z","timestamp":1745100437000},"page":"80-84","source":"Crossref","is-referenced-by-count":1,"title":["A CASE OF PELVIC AND INGUINAL LYMPH NODE RECURRENCE OF PENILE CANCER FOR WHICH TIP (PACLITAXEL, IFOSFAMIDE, CISPLATIN) THERAPY WAS EFFECTIVE","TIP\uff08Paclitaxel\uff0cIfosfamide\uff0cCisplatin\uff09\u7642\u6cd5\u304c\u8457\u52b9\u3057\u305f\u9670\u830e\u764c\u9aa8\u76e4\u30fb\u9f20\u5f84\u30ea\u30f3\u30d1\u7bc0\u518d\u767a\u306e1\u4f8b"],"prefix":"10.5980","volume":"115","author":[{"given":"Noriaki","family":"Noto","sequence":"first","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reona","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyun","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimio","family":"Chiba","sequence":"additional","affiliation":[{"name":"Department of Urology, Fujisaw City Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Yamada Y, Gohji K, Hara T, Sugiyama T, Arakawa S and Kamidono S: Long-term followup study of penile cancer. Int J Urol, 5, 247-251, 1998.","DOI":"10.1111\/j.1442-2042.1998.tb00598.x"},{"key":"2","unstructured":"2) EAU guidelines on penile cancer, 2018."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Reich O, Pickel H and P\u00fcrstner P: Exfoliative cytological of a lymphoepithelioma carcinoma in cervical smear. Acta Cytol, 43, 285-288, 1999.","DOI":"10.1159\/000330995"},{"key":"4","unstructured":"4) \u548c\u7530\u61b2\u660e, \u69d9\u539f\u5eb7\u4eae, \u6e4a \u6676\u898f, \u4e0a\u9818\u983c\u4e4b, \u4e2d\u5cf6\u4fe1\u80fd, \u6e21\u8fba\u79c0\u5e78, \u4e45\u5ca1\u6b63\u5178, \u6ff1\u7530\u54f2\u592b: \u8180\u80f1Lymphoepithelioma-like carcinoma\u306e1\u4f8b. \u8a3a\u65ad\u75c5\u7406, 30 (2), 103, 2013."},{"key":"5","unstructured":"5) \u65e5\u91ce\u4f51\u7f8e, \u5411\u7530\u79c0\u5247, \u591a\u5e7e\u5c71\u6e09: \u8853\u524d\u5316\u5b66\u7642\u6cd5\u304c\u8457\u52b9\u3057\u305f\u98df\u9053\u539f\u767alymphoepithelioma-like carcinoma\u306e1\u5207\u9664\u4f8b. \u65e5\u6d88\u5916\u4f1a\u8a8c, 44 (11), 1371-1379, 2011."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Graafland NM, Moonen LM, Boven HH, Werkhoven E, Kerst JM and Horenblas S: Inguinal recurrence following therapeutic lymphadenectomy for node positive penile carcinoma: outcome and implications for Management. J Urol, 185, 888-893, 2011.","DOI":"10.1016\/j.juro.2010.10.059"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Srinivas V, Morse MJ, Herr HW, Sogani PC and Whitmore WF: Penile cancer: relation of extent of nodal metastasis to survival. J Urol, 137, 880-882, 1987.","DOI":"10.1016\/S0022-5347(17)44281-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF and Pettaway CA: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. Int J Clin Oncol, 28, 3851-3857, 2010.","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"9","unstructured":"9) \u4e45\u4fdd\u7530\u6075\u7ae0, \u4ef2\u91ce\u6b63\u535a, \u6c38\u4e95\u771f\u543e, \u677e\u5ca1\u52a0\u6075, \u8352\u5ddd\u88d5\u8cb4, \u5800\u6c5f\u61b2\u543e, \u51fa\u53e3 \u9686, \u52a0\u85e4\u4e45\u548c: TIP (Paclitaxel,Ifosfamide, Cisplatin) \u7642\u6cd5\u304c\u8457\u52b9\u3057\u305f\u9f20\u5f84\u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u3092\u6709\u3059\u308b\u9670\u830e\u764c\u306e1\u4f8b. \u6ccc\u5c3f\u7d00\u8981, 61, 33-37, 2015."},{"key":"10","unstructured":"10) \u9ad8\u672c\u5927\u8def, \u6625\u65e5 \u7d14, \u6e6f\u6751 \u5be7, \u5c0f\u6cc9\u5145\u4e4b, \u82b1\u4e95\u5b5d\u5b8f, \u77f3\u7530\u5bdb\u660e, \u670d\u90e8\u7950\u4ecb, \u5bfa\u897f\u7d14\u4e00, \u4e09\u597d\u5eb7\u79c0, \u8fd1\u85e4\u6176\u4e00, \u91ce\u53e3\u548c\u7f8e: TPF (Paclitaxel,Cisplatin,5-Fluorouracil) \u7642\u6cd5\u3092\u65bd\u884c\u3057\u305f\u9032\u884c\u6027\u9670\u830e\u764c\u306e1\u4f8b. \u6ccc\u5c3f\u7d00\u8981, 60, 95-98, 2014."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Matsuda Y, Nishiyama N, Shindo T and Masumori N: Clinical features of 4 patients who underwent neoadjuvant chemotherapy for the locally advanced penile cancer. Int Canc Conf J, 6, 76-79, 2017.","DOI":"10.1007\/s13691-017-0278-x"},{"key":"12","unstructured":"12) \u6238\u9ad8\u96c5\u5e83, \u4e95\u4e0a \u4eab, \u4e09\u6728\u5927\u8f14, \u9ad8\u6a4b \u525b, \u6b66\u4e95\u822a\u5e73, \u7532\u6590\u535a\u5b9c, \u5ca9\u5d0e\u548c\u7bc4, \u6f81\u8c37\u5fe0\u6b63, \u5e73\u4e95\u5065\u4e00, \u5b89\u85e4\u5fe0\u52a9, \u79e6 \u8061\u5b5d, \u4e09\u80a1\u6d69\u5149: \u30ea\u30f3\u30d1\u7bc0\u8ee2\u79fb\u3092\u6709\u3059\u308b\u9670\u830e\u764c\u306b\u5bfe\u3057\u3066\u8853\u524dTIP\u7642\u6cd5\u304c\u6709\u52b9\u3067\u3042\u3063\u305f1\u4f8b. \u897f\u65e5\u6ccc\u5c3f, 82, 308-312, 2020."}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/2\/115_80\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:05:18Z","timestamp":1745640318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/115\/2\/115_80\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,20]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.115.80","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,20]]}}}